JPWO2019002875A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019002875A5 JPWO2019002875A5 JP2019571667A JP2019571667A JPWO2019002875A5 JP WO2019002875 A5 JPWO2019002875 A5 JP WO2019002875A5 JP 2019571667 A JP2019571667 A JP 2019571667A JP 2019571667 A JP2019571667 A JP 2019571667A JP WO2019002875 A5 JPWO2019002875 A5 JP WO2019002875A5
- Authority
- JP
- Japan
- Prior art keywords
- stip
- stap
- molecule
- bfl
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000001014 amino acid Nutrition 0.000 claims description 118
- 150000001413 amino acids Chemical class 0.000 claims description 117
- 229920000272 Oligonucleotide Polymers 0.000 claims description 74
- 238000004132 cross linking Methods 0.000 claims description 29
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims description 27
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims description 24
- 150000003951 lactams Chemical class 0.000 claims description 23
- 230000014509 gene expression Effects 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- 206010013801 Duchenne muscular dystrophy Diseases 0.000 claims description 18
- -1 N-β-maleimidopropyl-oxysuccinimide ester Chemical class 0.000 claims description 12
- 230000000975 bioactive Effects 0.000 claims description 12
- IZCVLYJVVCABBV-UHFFFAOYSA-N 2-hydrazinylpyridine-3-carboxylic acid Chemical compound NNC1=NC=CC=C1C(O)=O IZCVLYJVVCABBV-UHFFFAOYSA-N 0.000 claims description 11
- 108010069091 Dystrophin Proteins 0.000 claims description 11
- 230000001588 bifunctional Effects 0.000 claims description 11
- 229920001223 polyethylene glycol Polymers 0.000 claims description 11
- 239000004472 Lysine Substances 0.000 claims description 10
- 238000005865 alkene metathesis reaction Methods 0.000 claims description 10
- 150000001412 amines Chemical class 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- 239000004971 Cross linker Substances 0.000 claims description 8
- 208000008466 Metabolic Disease Diseases 0.000 claims description 8
- 206010053643 Neurodegenerative disease Diseases 0.000 claims description 8
- 208000006883 Neuromuscular Disease Diseases 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 210000000170 Cell Membrane Anatomy 0.000 claims description 7
- 229960002989 Glutamic Acid Drugs 0.000 claims description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 6
- 206010047461 Viral infection Diseases 0.000 claims description 6
- 208000001756 Virus Disease Diseases 0.000 claims description 6
- 201000010870 diseases of metabolism Diseases 0.000 claims description 6
- 235000013922 glutamic acid Nutrition 0.000 claims description 6
- 239000004220 glutamic acid Substances 0.000 claims description 6
- 230000000149 penetrating Effects 0.000 claims description 6
- 239000000546 pharmaceutic aid Substances 0.000 claims description 6
- 230000017613 viral reproduction Effects 0.000 claims description 6
- 229960005261 Aspartic Acid Drugs 0.000 claims description 5
- 235000003704 aspartic acid Nutrition 0.000 claims description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 5
- NMHMNPHRMNGLLB-UHFFFAOYSA-N Phloretic acid Chemical group OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 4
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims description 4
- JKHVDAUOODACDU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCN1C(=O)C=CC1=O JKHVDAUOODACDU-UHFFFAOYSA-N 0.000 claims description 2
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 claims description 2
- IHVODYOQUSEYJJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]amino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)C(CC1)CCC1CN1C(=O)C=CC1=O IHVODYOQUSEYJJ-UHFFFAOYSA-N 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-L glutarate(2-) Chemical compound [O-]C(=O)CCCC([O-])=O JFCQEDHGNNZCLN-UHFFFAOYSA-L 0.000 claims description 2
- 101700077824 CNN1 Proteins 0.000 claims 5
- 102100006947 TAGLN Human genes 0.000 claims 5
- 101710025884 TAGLN Proteins 0.000 claims 5
- 102100014129 DMD Human genes 0.000 claims 1
- 210000004027 cells Anatomy 0.000 description 115
- 229940019746 Antifibrinolytic amino acids Drugs 0.000 description 86
- 102000004196 processed proteins & peptides Human genes 0.000 description 61
- 108090000765 processed proteins & peptides Proteins 0.000 description 61
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 42
- 102000019679 Cell-Penetrating Peptides Human genes 0.000 description 42
- 238000007363 ring formation reaction Methods 0.000 description 38
- 150000001875 compounds Chemical class 0.000 description 32
- 239000003814 drug Substances 0.000 description 30
- 229940079593 drugs Drugs 0.000 description 29
- 125000000524 functional group Chemical group 0.000 description 21
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 19
- 239000000074 antisense oligonucleotide Substances 0.000 description 19
- 230000021615 conjugation Effects 0.000 description 19
- 125000005647 linker group Chemical group 0.000 description 19
- 238000000034 method Methods 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 18
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 17
- 230000000087 stabilizing Effects 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000011347 resin Substances 0.000 description 16
- 229920005989 resin Polymers 0.000 description 16
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 15
- 238000010586 diagram Methods 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 14
- 230000003993 interaction Effects 0.000 description 14
- 238000000684 flow cytometry Methods 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 12
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 11
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 230000001988 toxicity Effects 0.000 description 11
- 231100000419 toxicity Toxicity 0.000 description 11
- 102000001039 Dystrophin Human genes 0.000 description 10
- 229920000665 Exon Polymers 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 230000004700 cellular uptake Effects 0.000 description 10
- 238000006798 ring closing metathesis reaction Methods 0.000 description 10
- 230000003612 virological Effects 0.000 description 10
- GOUHYARYYWKXHS-UHFFFAOYSA-N 4-formylbenzoic acid Chemical compound OC(=O)C1=CC=C(C=O)C=C1 GOUHYARYYWKXHS-UHFFFAOYSA-N 0.000 description 9
- 230000001808 coupling Effects 0.000 description 9
- 238000005859 coupling reaction Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000005755 formation reaction Methods 0.000 description 9
- 230000000670 limiting Effects 0.000 description 9
- 235000018977 lysine Nutrition 0.000 description 9
- 229960003646 lysine Drugs 0.000 description 9
- 238000007492 two-way ANOVA Methods 0.000 description 9
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 8
- 235000018417 cysteine Nutrition 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 8
- 239000004215 Carbon black (E152) Substances 0.000 description 7
- 208000003703 Viral Hemorrhagic Fevers Diseases 0.000 description 7
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 230000002708 enhancing Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000006011 modification reaction Methods 0.000 description 7
- 230000001264 neutralization Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 150000003573 thiols Chemical class 0.000 description 7
- 210000001519 tissues Anatomy 0.000 description 7
- 150000001336 alkenes Chemical class 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 239000000562 conjugate Substances 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 150000002429 hydrazines Chemical class 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 230000002829 reduced Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 150000003852 triazoles Chemical class 0.000 description 6
- UCMIRNVEIXFBKS-UHFFFAOYSA-N β-Alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 6
- 230000036912 Bioavailability Effects 0.000 description 5
- 210000002216 Heart Anatomy 0.000 description 5
- 108020004999 Messenger RNA Proteins 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 125000004429 atoms Chemical group 0.000 description 5
- 230000035514 bioavailability Effects 0.000 description 5
- 238000002983 circular dichroism Methods 0.000 description 5
- 229920002106 messenger RNA Polymers 0.000 description 5
- 230000002194 synthesizing Effects 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- WWIYQJITPCEFGT-UHFFFAOYSA-N 1,4-bis(ethenyl)benzene;(4-methylphenyl)-phenylmethanamine;styrene;hydrochloride Chemical compound Cl.C=CC1=CC=CC=C1.C=CC1=CC=C(C=C)C=C1.C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 WWIYQJITPCEFGT-UHFFFAOYSA-N 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 4
- 210000004556 Brain Anatomy 0.000 description 4
- IRXSLJNXXZKURP-UHFFFAOYSA-N Fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
- 210000003205 Muscles Anatomy 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 229960003121 arginine Drugs 0.000 description 4
- 238000010462 azide-alkyne Huisgen cycloaddition reaction Methods 0.000 description 4
- 150000001735 carboxylic acids Chemical class 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 230000001413 cellular Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 238000010930 lactamization Methods 0.000 description 4
- 239000002609 media Substances 0.000 description 4
- 230000001404 mediated Effects 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 230000014621 translational initiation Effects 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- HTFFMYRVHHNNBE-YFKPBYRVSA-N (2S)-2-amino-6-azidohexanoic acid Chemical compound OC(=O)[C@@H](N)CCCCN=[N+]=[N-] HTFFMYRVHHNNBE-YFKPBYRVSA-N 0.000 description 3
- 150000000177 1,2,3-triazoles Chemical class 0.000 description 3
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 3
- 229920002395 Aptamer Polymers 0.000 description 3
- 230000037177 Biodistribution Effects 0.000 description 3
- 101710006133 NECAB1 Proteins 0.000 description 3
- 229920001850 Nucleic acid sequence Polymers 0.000 description 3
- 210000001324 Spliceosomes Anatomy 0.000 description 3
- 241000376353 Stips Species 0.000 description 3
- 101710032928 TFIP11 Proteins 0.000 description 3
- ZHHGTMQHUWDEJF-UHFFFAOYSA-N [(6-chlorobenzotriazol-1-yl)oxy-(dimethylamino)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.C1=C(Cl)C=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 ZHHGTMQHUWDEJF-UHFFFAOYSA-N 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 150000001345 alkine derivatives Chemical group 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 238000006254 arylation reaction Methods 0.000 description 3
- 229940000635 beta-Alanine Drugs 0.000 description 3
- 230000000903 blocking Effects 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000001419 dependent Effects 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 150000002019 disulfides Chemical class 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000001976 improved Effects 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000008191 permeabilizing agent Substances 0.000 description 3
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000002110 toxicologic Effects 0.000 description 3
- 231100000723 toxicological property Toxicity 0.000 description 3
- 230000001131 transforming Effects 0.000 description 3
- ZXOKSWZUJXKQCQ-NRFANRHFSA-N (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-2-methylpent-4-ynoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@](CC#C)(C)C(O)=O)C3=CC=CC=C3C2=C1 ZXOKSWZUJXKQCQ-NRFANRHFSA-N 0.000 description 2
- FSBNDYYRTZBHAN-LURJTMIESA-N (2S)-2-amino-2-methylpent-4-ynoic acid Chemical compound OC(=O)[C@](N)(C)CC#C FSBNDYYRTZBHAN-LURJTMIESA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 2
- UQGQELCVCLGAFH-UHFFFAOYSA-N 2-aminohept-3-enoic acid Chemical compound CCCC=CC(N)C(O)=O UQGQELCVCLGAFH-UHFFFAOYSA-N 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- 101700044058 CYGB Proteins 0.000 description 2
- 229940107161 Cholesterol Drugs 0.000 description 2
- 229920002759 Circular DNA Polymers 0.000 description 2
- 108020004638 Circular DNA Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 210000004185 Liver Anatomy 0.000 description 2
- 108010066154 Nuclear Export Signals Proteins 0.000 description 2
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 2
- 101710004054 PMFBP1 Proteins 0.000 description 2
- 229940067631 Phospholipids Drugs 0.000 description 2
- 230000036141 SERUM STABILITY Effects 0.000 description 2
- 208000002320 Spinal Muscular Atrophy Diseases 0.000 description 2
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 2
- 229920000401 Three prime untranslated region Polymers 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 108090001123 antibodies Proteins 0.000 description 2
- 102000004965 antibodies Human genes 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000001142 circular dichroism spectrum Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000003260 fluorescence intensity Methods 0.000 description 2
- 150000004676 glycans Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000002458 infectious Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000011068 load Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 230000030147 nuclear export Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 108010043655 penetratin Proteins 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 230000001402 polyadenylating Effects 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002250 progressing Effects 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- 230000000754 repressing Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- WMQPXXOMYXZNQY-UHFFFAOYSA-N (2,4-dimethoxyphenyl)-(4-methoxyphenyl)methanol Chemical compound C1=CC(OC)=CC=C1C(O)C1=CC=C(OC)C=C1OC WMQPXXOMYXZNQY-UHFFFAOYSA-N 0.000 description 1
- FSBNDYYRTZBHAN-ZCFIWIBFSA-N (2R)-2-amino-2-methylpent-4-ynoic acid Chemical compound OC(=O)[C@@](N)(C)CC#C FSBNDYYRTZBHAN-ZCFIWIBFSA-N 0.000 description 1
- PJRFTUILPGJJIO-IBGZPJMESA-N (2S)-6-azido-2-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCN=[N+]=[N-])C(=O)O)C3=CC=CC=C3C2=C1 PJRFTUILPGJJIO-IBGZPJMESA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- CQYYGCVORGQMEQ-UHFFFAOYSA-M 2,5-dioxopyrrolidine-1-carboxylate Chemical compound [O-]C(=O)N1C(=O)CCC1=O CQYYGCVORGQMEQ-UHFFFAOYSA-M 0.000 description 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N Alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N Aminocaproic acid Chemical group NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 108010003596 Antennapedia Homeodomain Protein Proteins 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 210000001367 Arteries Anatomy 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- RTIIDBURLHHYRK-ZETCQYMHSA-N CCCC=CN[C@@H](C)C(O)=O Chemical compound CCCC=CN[C@@H](C)C(O)=O RTIIDBURLHHYRK-ZETCQYMHSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010091307 Catalytic DNA Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 229920001880 Circular RNA Polymers 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101710003775 ERVK-10 Proteins 0.000 description 1
- 101710037030 ERVK-11 Proteins 0.000 description 1
- 101710009283 ERVK-18 Proteins 0.000 description 1
- 101710009286 ERVK-19 Proteins 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 101710035700 ERVK-25 Proteins 0.000 description 1
- 101710038044 ERVK-6 Proteins 0.000 description 1
- 101710014468 ERVK-7 Proteins 0.000 description 1
- 101710014482 ERVK-8 Proteins 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101710043924 HERVK_113 Proteins 0.000 description 1
- 206010018987 Haemorrhage Diseases 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 208000004731 Long QT Syndrome Diseases 0.000 description 1
- 101710029649 MDV043 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 229920001776 Mature messenger RNA Polymers 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 1
- 208000003627 Muscular Dystrophy Diseases 0.000 description 1
- 102000005665 Neurotransmitter Transport Proteins Human genes 0.000 description 1
- 108010084810 Neurotransmitter Transport Proteins Proteins 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N Ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229950001015 Nusinersen Drugs 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920002224 Peptide nucleic acid Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101700053158 RCM1 Proteins 0.000 description 1
- 230000025458 RNA interference Effects 0.000 description 1
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 1
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 1
- 101710006375 RNASEH1 Proteins 0.000 description 1
- 101700078434 RT67 Proteins 0.000 description 1
- 239000005092 Ruthenium Substances 0.000 description 1
- 101710017605 Rv2228c Proteins 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 108020004459 Small Interfering RNA Proteins 0.000 description 1
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 1
- 210000000278 Spinal Cord Anatomy 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 206010043554 Thrombocytopenia Diseases 0.000 description 1
- QHNORJFCVHUPNH-UHFFFAOYSA-L To-Pro-3 Chemical compound [I-].[I-].S1C2=CC=CC=C2[N+](C)=C1C=CC=C1C2=CC=CC=C2N(CCC[N+](C)(C)C)C=C1 QHNORJFCVHUPNH-UHFFFAOYSA-L 0.000 description 1
- NQPHMXWPDCSHTE-UHFFFAOYSA-N Trifluoromethanesulfonyl azide Chemical compound FC(F)(F)S(=O)(=O)N=[N+]=[N-] NQPHMXWPDCSHTE-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 210000002845 Virion Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- GPDHNZNLPKYHCN-DZOOLQPHSA-N [[(Z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-morpholin-4-ylmethylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CCOC(=O)C(\C#N)=N/OC(=[N+](C)C)N1CCOCC1 GPDHNZNLPKYHCN-DZOOLQPHSA-N 0.000 description 1
- UQYZFNUUOSSNKT-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 UQYZFNUUOSSNKT-UHFFFAOYSA-N 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 150000003934 aromatic aldehydes Chemical class 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- OYSSCEMVGJEQHM-UHFFFAOYSA-N benzene-1,3-dicarbonyl azide Chemical compound [N-]=[N+]=NC(=O)C1=CC=CC(C(=O)N=[N+]=[N-])=C1 OYSSCEMVGJEQHM-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000000740 bleeding Effects 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 238000009933 burial Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000027448 caveolin-mediated endocytosis Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- 230000006395 clathrin-mediated endocytosis Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000536 complexating Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001010 compromised Effects 0.000 description 1
- 230000001268 conjugating Effects 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000001351 cycling Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000000368 destabilizing Effects 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- NDDFAYQFCZRYDT-UHFFFAOYSA-L dichlororuthenium;tricyclohexyl-[phenyl(tricyclohexylphosphaniumyl)methyl]phosphanium Chemical compound Cl[Ru]Cl.C1CCCCC1[P+](C1CCCCC1)(C1CCCCC1)C([P+](C1CCCCC1)(C1CCCCC1)C1CCCCC1)C1=CC=CC=C1 NDDFAYQFCZRYDT-UHFFFAOYSA-L 0.000 description 1
- AJDPNPAGZMZOMN-UHFFFAOYSA-N diethyl (4-oxo-1,2,3-benzotriazin-3-yl) phosphate Chemical compound C1=CC=C2C(=O)N(OP(=O)(OCC)OCC)N=NC2=C1 AJDPNPAGZMZOMN-UHFFFAOYSA-N 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 239000007925 intracardiac injection Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 101700045377 mvp1 Proteins 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000011528 polyamide (building material) Substances 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000268 renotropic Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012508 resin bead Substances 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229920002033 ribozyme Polymers 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 101700086982 rnh Proteins 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Substances [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000000576 supplementary Effects 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100000224 toxic side effect Toxicity 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023107560A JP2023126866A (ja) | 2017-06-28 | 2023-06-29 | 改善された薬物送達のためのステープル又はステッチペプチドを含む化合物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1710322.7 | 2017-06-28 | ||
GB1710322.7A GB2563875B (en) | 2017-06-28 | 2017-06-28 | Improvements in drug delivery |
PCT/GB2018/051818 WO2019002875A1 (en) | 2017-06-28 | 2018-06-28 | COMPOUNDS COMPRISING ATTACHED OR BINDED PEPTIDES FOR ENHANCED MEDICATION DELIVERY |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023107560A Division JP2023126866A (ja) | 2017-06-28 | 2023-06-29 | 改善された薬物送達のためのステープル又はステッチペプチドを含む化合物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2020525462A JP2020525462A (ja) | 2020-08-27 |
JP2020525462A5 JP2020525462A5 (ja) | 2021-08-05 |
JPWO2019002875A5 true JPWO2019002875A5 (ko) | 2022-11-15 |
Family
ID=59523726
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019571667A Pending JP2020525462A (ja) | 2017-06-28 | 2018-06-28 | 改善された薬物送達のためのステープル又はステッチペプチドを含む化合物 |
JP2023107560A Pending JP2023126866A (ja) | 2017-06-28 | 2023-06-29 | 改善された薬物送達のためのステープル又はステッチペプチドを含む化合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023107560A Pending JP2023126866A (ja) | 2017-06-28 | 2023-06-29 | 改善された薬物送達のためのステープル又はステッチペプチドを含む化合物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220062431A1 (ko) |
EP (1) | EP3645047A1 (ko) |
JP (2) | JP2020525462A (ko) |
KR (1) | KR20200019742A (ko) |
CN (1) | CN110997007A (ko) |
AU (1) | AU2018293439A1 (ko) |
BR (1) | BR112019027880A2 (ko) |
CA (1) | CA3068377A1 (ko) |
GB (1) | GB2563875B (ko) |
WO (1) | WO2019002875A1 (ko) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
AU2021314310A1 (en) * | 2020-07-22 | 2023-03-16 | Fog Pharmaceuticals, Inc. | Stapled peptides and methods thereof |
WO2024069229A2 (en) | 2022-08-03 | 2024-04-04 | Sutura Therapeutics Ltd | Biologically active compounds |
KR102556415B1 (ko) | 2022-11-22 | 2023-07-18 | 주식회사 디킨코스메틱 | 에스쿨렌틴 유래 스테이플화된 펩타이드를 함유한 화장료 조성물 및 그 제조 방법 |
KR102615755B1 (ko) | 2023-01-06 | 2023-12-21 | 정용문 | 주름개선 기능성 펩타이드를 함유한 화장료 조성물 및 이를 포함하는 마스크팩 및 앰플 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2693048C (en) * | 2007-07-12 | 2016-10-18 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs or tissues |
WO2009149214A2 (en) * | 2008-06-03 | 2009-12-10 | Aileron Therapeutics, Inc. | Compositions and methods for enhancing cellular transport of biomolecules |
WO2013150338A1 (en) * | 2012-04-04 | 2013-10-10 | Centre National De La Recherche Scientifique | Stapled cell penetrating peptides for intracellular delivery of molecules |
CA2895578A1 (en) * | 2012-12-19 | 2014-06-26 | Nils A. KULAK | Reaction vessel for sample preparation |
JP6954843B2 (ja) * | 2015-05-19 | 2021-10-27 | サレプタ セラピューティクス,インコーポレイテッド | ペプチドオリゴヌクレオチドコンジュゲート |
WO2017011820A2 (en) * | 2015-07-15 | 2017-01-19 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
GB2545898B (en) * | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
-
2017
- 2017-06-28 GB GB1710322.7A patent/GB2563875B/en active Active
-
2018
- 2018-06-28 CN CN201880052240.2A patent/CN110997007A/zh active Pending
- 2018-06-28 KR KR1020207002415A patent/KR20200019742A/ko not_active Application Discontinuation
- 2018-06-28 AU AU2018293439A patent/AU2018293439A1/en active Pending
- 2018-06-28 US US16/626,476 patent/US20220062431A1/en active Pending
- 2018-06-28 BR BR112019027880-0A patent/BR112019027880A2/pt unknown
- 2018-06-28 EP EP18755531.3A patent/EP3645047A1/en active Pending
- 2018-06-28 JP JP2019571667A patent/JP2020525462A/ja active Pending
- 2018-06-28 CA CA3068377A patent/CA3068377A1/en active Pending
- 2018-06-28 WO PCT/GB2018/051818 patent/WO2019002875A1/en active Search and Examination
-
2023
- 2023-06-29 JP JP2023107560A patent/JP2023126866A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11944688B2 (en) | Biologically active compounds | |
JP2023126866A (ja) | 改善された薬物送達のためのステープル又はステッチペプチドを含む化合物 | |
CA2846218C (en) | Cell-penetrating peptides having a central hydrophobic domain | |
US20140140929A1 (en) | Chemically modified cell-penetrating peptides for improved delivery of gene modulating compounds | |
CN112789031B (zh) | 用于核酸递送的包含脂化的阳离子肽化合物的脂质纳米颗粒制剂 | |
JP2017517253A (ja) | ペプチド担体上の多重オリゴヌクレオチド部分 | |
Dastpeyman et al. | Modular synthesis of trifunctional peptide-oligonucleotide conjugates via native chemical ligation | |
JPWO2017109494A5 (ko) | ||
JPWO2019002875A5 (ko) | ||
GB2580569A (en) | Improvements in drug delivery | |
WO2024069229A2 (en) | Biologically active compounds | |
GB2574525A (en) | Improvements in drug delivery | |
US20030207400A1 (en) | Vectors for dna delivery | |
JP2022502347A (ja) | 細胞透過性ペプチド |